Vanguard Global Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.3M Buy
24,196
+542
+2% +$57.8K ﹤0.01% 1155
2026
Q2
$2.63M Sell
23,654
-6,046
-20% -$547K ﹤0.01% 1095
2026
Q1
$2.58M Buy
+29,700
New +$2.89M ﹤0.01% 1034

Other funds holding RYTM

Vanguard Global Advisers's RYTM Position: Q3 2026 in Review

Vanguard Global Advisers increased its Rhythm Pharmaceuticals (RYTM) stake by 2.3% in Q3 2026, buying an estimated $57.8K and bringing the position to 24,196 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1155.

Vanguard Global Advisers first reported a position in RYTM in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.63M in Q2 2026. 334 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Vanguard Global Advisers held 24,196 shares of Rhythm Pharmaceuticals worth $2.3M as of Q3 2026.
  • Vanguard Global Advisers bought 542 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $57.8K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1155 holding.
  • Vanguard Global Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Rhythm Pharmaceuticals position peaked at $2.63M in Q2 2026.
  • 334 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.